Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Amneal Seeks Dismissal as Defendant in Amgen v. Adello Filgrastim Biosimilar Suit

Related Content

Year in Review: Top Biosimilars-Related Regulatory Developments of 2022

Celltrion USA Announces Submission of BLA for Subcutaneous Infliximab Biosimilar

BPCIA Aflibercept Litigation: Regeneron Files 12(c) Motion to Dismiss Mylan’s Counterclaim for Inequitable Conduct

Now Available! Updated Goodwin’s Guide to Biosimilars Litigation and Regulation in the U.S., 2022-2023

FDA Accepts Biogen’s aBLA for Tocilizumab

Fresenius Kabi Announces FDA Approval of Adalimumab Biosimilar

BPCIA Aflibercept Litigation: Mylan Seeks Leave to Add a Declaratory Judgment Counterclaim of No Lost Profits or Injunctive Relief

Regeneron Files Expedited Motion Challenging Mylan’s Designation of Entire aBLA Production as Outside Counsel’s Eyes Only

LMG Recognizes Goodwin Lawyers and Practices for Excellence in Life Sciences

Goodwin Releases Update to its Comprehensive Guide to Biosimilars Litigation and Regulation in the U.S.

Goodwin Named an LMG Life Sciences Life Cycle Firm for the Tenth Consecutive Year

Goodwin Adds Life Sciences and Healthcare Litigation Partner William Jackson

China's Patent Linkage System: Can Strategies that Work in the U.S. System Be Applied to China?

Goodwin Named An LMG Life Sciences Life Cycle Firm For The Ninth Consecutive Year

ACI's 11th Summit on Biosimilars & Innovator Biologics

Navigating Hatch-Waxman and Biologic Litigation Amid the Coronavirus Pandemic

Life Sciences

Hatch-Waxman, Biologics and Biosimilars Litigation